Grifols, (GRFS) Receives Daily News Impact Score of 0.15
News headlines about Grifols, (NASDAQ:GRFS) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Grifols, earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.6440018463843 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern’s analysis:
- Have an eye on:- MGM Resorts International (NYSE:MGM), Grifols … – Market Breaking Point (press release) (journalfinance.net)
- Grifols, S.A. – American Deposi (NASDAQ:GRFS) Experiences … – Modern Readers (modernreaders.com)
- Technical Insights on Biotech Stocks — Grifols, Halozyme Therapeutics, Illumina, and VIVUS – PR Newswire (press release) (prnewswire.com)
- Grifols SA (GRFS) Seeing Increased Volatility in Session – FLBC News (flbcnews.com)
- Can Grifols SA (GRFS) Move Higher? – Evergreen Caller (evergreencaller.com)
Shares of Grifols, (NASDAQ:GRFS) opened at 20.61 on Tuesday. The firm has a market capitalization of $28.16 billion, a PE ratio of 43.03 and a beta of 1.00. The company has a 50 day moving average price of $20.54 and a 200-day moving average price of $20.06. Grifols, has a 12 month low of $14.27 and a 12 month high of $22.83.
GRFS has been the subject of a number of research analyst reports. Zacks Investment Research raised Grifols, from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Tuesday, July 4th. Bank of America Corporation reissued a “buy” rating on shares of Grifols, in a research report on Tuesday, July 4th. BidaskClub raised Grifols, from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Goldman Sachs Group, Inc. (The) cut Grifols, from a “buy” rating to a “neutral” rating in a research report on Friday, June 30th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Grifols, currently has an average rating of “Hold” and an average price target of $24.00.
TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/05/grifols-grfs-receives-daily-news-impact-score-of-0-15.html.
Grifols, Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Stock Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related stocks with our FREE daily email newsletter.